​

Syndax Pharmaceuticals (SNDX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SNDX Stock Forecast

Syndax Pharmaceuticals (SNDX) stock forecast, based on 21 Wall Street analysts, predicts a 12-month average price target of $26.50, with a high of $35.00 and a low of $18.00. This represents a 156.04% increase from the last price of $10.35.

$10 $15 $20 $25 $30 $35 High: $35 Avg: $26.5 Low: $18 Last Closed Price: $10.35

SNDX Stock Rating

Syndax Pharmaceuticals stock's rating consensus is Buy, based on 21 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 19 Buy (90.48%), 2 Hold (9.52%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 21 0 2 19 Strong Sell Sell Hold Buy Strong Buy

SNDX Price Target Upside V Benchmarks

TypeNameUpside
StockSyndax Pharmaceuticals156.04%
SectorHealthcare Stocks 19.91%
IndustryBiotech Stocks 55.52%

Price Target Trends

1M3M12M
# Anlaysts228
Avg Price Target$26.50$26.50$29.50
Last Closing Price$10.35$10.35$10.35
Upside/Downside156.04%156.04%185.02%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 25291--12
Jun, 25291--12
May, 25391--13
Apr, 254101--15
Mar, 254101--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 15, 2025David DaiUBS$35.00$9.80257.14%238.16%
Jul 10, 2025Corinne JohnsonGoldman Sachs$18.00$9.8283.30%73.91%
Nov 13, 2024George FarmerScotiabank$18.00$20.04-10.18%73.91%
Oct 24, 2024David DaiUBS$37.00$18.5499.57%257.49%
Aug 15, 2024Yigal NochomovitzCitigroup$34.00$20.0969.24%228.50%
Aug 15, 2024Jason ZemanskyBank of America Securities$31.00$19.5858.32%199.52%
Aug 15, 2024Peter LawsonBarclays$33.00$19.5868.54%218.84%
Jul 30, 2024Jason ZemanskyBank of America Securities$30.00$21.9936.43%189.86%
Jun 28, 2024Kelly ShiJefferies$37.00$20.3282.09%257.49%
May 09, 2024Bradley CaninoStifel Nicolaus$40.00$22.3878.73%286.47%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 15, 2025UBSBuyBuyhold
Jul 10, 2025Goldman SachsBuyBuyinitialise
May 06, 2025ScotiabankSector PerformSector Performhold
Nov 13, 2024ScotiabankSector PerformSector Performhold
Oct 24, 2024UBSBuyinitialise
Aug 15, 2024Cowen & Co.BuyBuyhold
Aug 15, 2024CitigroupBuyBuyhold
Aug 15, 2024H.C. WainwrightBuyBuyhold
Aug 15, 2024BarclaysOverweightOverweighthold
Jul 30, 2024Bank of America SecuritiesBuyBuyhold

Financial Forecast

EPS Forecast

$-9 $-7 $-5 $-3 $-1 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.77$0.48$-2.37$-2.98$-3.73----
Avg Forecast$-1.86$-2.04$-2.53$-2.95$-3.48$-3.85$-2.65$-1.64$-0.32
High Forecast$-0.67$-0.73$-0.41$-2.88$-2.85$-3.24$-0.74$-0.96$-0.13
Low Forecast$-4.20$-4.60$-8.09$-3.13$-3.67$-4.50$-3.45$-2.43$-0.74
Surprise %-4.84%-123.53%-6.32%1.02%7.18%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.52M$139.71M--$23.68M----
Avg Forecast$1.47M$19.15M$375.00K-$48.72M$98.48M$234.54M$347.18M$537.00M
High Forecast$2.88M$37.59M$1.01M-$134.94M$132.74M$234.55M$688.50M$1.06B
Low Forecast$740.87K$9.68M$132.85K-$23.22M$59.51M$234.52M$184.39M$285.21M
Surprise %3.54%629.55%---51.40%----

Net Income Forecast

$-600M $-470M $-340M $-210M $-80M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-73.07M$24.93M$-143.75M$-209.36M$-318.76M----
Avg Forecast$-131.15M$-143.68M$-178.14M$-209.36M$-229.54M$-272.53M$-240.79M$-124.49M$-22.82M
High Forecast$-46.87M$-51.34M$-28.60M$-202.38M$-200.80M$-228.32M$-52.08M$-67.65M$-8.91M
Low Forecast$-295.33M$-323.55M$-569.42M$-220.52M$-258.27M$-316.74M$-242.60M$-171.23M$-51.99M
Surprise %-44.28%-117.35%-19.31%-38.87%----

SNDX Forecast FAQ

Is Syndax Pharmaceuticals stock a buy?

Syndax Pharmaceuticals stock has a consensus rating of Buy, based on 21 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 19 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Syndax Pharmaceuticals is a favorable investment for most analysts.

What is Syndax Pharmaceuticals's price target?

Syndax Pharmaceuticals's price target, set by 21 Wall Street analysts, averages $26.5 over the next 12 months. The price target range spans from $18 at the low end to $35 at the high end, suggesting a potential 156.04% change from the previous closing price of $10.35.

How does Syndax Pharmaceuticals stock forecast compare to its benchmarks?

Syndax Pharmaceuticals's stock forecast shows a 156.04% upside, outperforming the average forecast for the healthcare stocks sector (19.91%) and outperforming the biotech stocks industry (55.52%).

What is the breakdown of analyst ratings for Syndax Pharmaceuticals over the past three months?

  • July 2025: 16.67% Strong Buy, 75.00% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 16.67% Strong Buy, 75.00% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 23.08% Strong Buy, 69.23% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.

What is Syndax Pharmaceuticals’s EPS forecast?

Syndax Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.85, marking a 3.22% increase from the reported $-3.73 in 2024. Estimates for the following years are $-2.65 in 2026, $-1.64 in 2027, and $-0.32 in 2028.

What is Syndax Pharmaceuticals’s revenue forecast?

Syndax Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $98.48M, reflecting a 315.88% increase from the reported $23.68M in 2024. The forecast for 2026 is $234.54M, followed by $347.18M for 2027, and $537M for 2028.

What is Syndax Pharmaceuticals’s net income forecast?

Syndax Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-273M, representing a -14.50% decrease from the reported $-319M in 2024. Projections indicate $-241M in 2026, $-124M in 2027, and $-22.823M in 2028.